intracellular pathogens. Other macrophage products induced by interferon-y are major histocompatibility complex (MHC) class II antigens, Fc receptors, the leukocyte adhesion protein LFA1, endotoxin binding sites, and the receptor for the endotoxin-lipopolysaccharide-binding protein complex (CD14). Interferon-y also modulates CD4 + helper T-cell function by regulating interleukin-4, interleukin-5, and interleukin-10. Of particular interest is that interleukin-4 inhibits many activities of interferon-y, such as production of reactive oxygen products and the inhibitory effects of interferon-y on IgE synthesis.
Interferon-y activates endothelial cells, fibroblasts, epithelial cells, hepatocytes, and macrophages to kill intracellular pathogens such as Mycobacterium, Leishmania, Toxoplasma, Rickettsia, and Chlamydia species. Recently, interferon-y has been shown to reduce the incidence of infections in patients with chronic granulomatous disease and to be an important adjuvant for the treatment of certain intracellular parasites (7) .
Mechanisms of Action
Dr. Joshua M. Farber (Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases): The biological effects of interferon-y, like those of interferon-a and -]8, result primarily from the enhanced expression of a collection of genes and proteins in responsive cells (8) . Interferon-y has a six-helix monomer structure and exists as a symmetric, antiparallel homodimer that induces dimerization of its receptor ( Figure 1 ) (9) . The interferon-y receptor consists of at least two components, a 90-kd glycoprotein (a) that is able to bind ligands (10) and a structurally related putative transmembrane protein that is necessary for signaling (/3) (11) .
Signaling through the interferon-y receptor requires Jakl and Jak2 (12) , two members of a family of tyrosine kinases. By analogy with other systems involving the Jakfamily kinases, the interferon-y receptor and the Jak kinases probably exist in a preformed complex before ligand binding. Binding of interferon-y leads to the phosphorylation of the interferon-y receptor (13) and of Jakl and Jak2 on tyrosine residues; this is presumed to lead to their activation. Jakl and Jak2 are each necessary for the phosphorylation of the other after interferon-y binds to its receptor. This requirement is the basis for imagining the juxtaposition of the Jak kinases on receptor dimerization, although the details of the interactions among the kinases and the receptor subunits are not known ( Figure   1 ). Jak-kinase activation leads, either directly or indirectly, to the phosphorylation on tyrosine of the 91-kd latent cytoplasmic factor Static* (S [ignal] transducer] and a [ctivator] of transcription]) protein, which in turn leads to the formation of Static* homodimers, mediated through protein domains (Src homology 2 domains) that bind tyrosine-phosphorylated proteins (14) . Once phosphorylated and dimerized, Static* moves from the cytoplasm to the nucleus, where it binds to regulatory regions of genes containing GAS (g[amma interferon] a[ctivation] s[ite]) sequences. The GAS sequence (consensus TTNCNNNAA) was the first well-defined promoter element identified as specifically related to interferon-y-dependent gene activation (15) , and GAS-like sequences typically have been found in interferon-y-inducible genes and serve as binding sites for Static*. Nonetheless, sequences in addition to GAS are clearly important for the activation of some genes by interferon-y (16, 17) . Although it appears that Static* dimers are able to bind to a core GAS site without other proteins, evidence indicates that Static* does form complexes one or more other proteins, as yet unknown, when binding to the regulatory regions of interferon-yactivated genes (17) . The signaling events in response to interferon-y rely solely on preformed components and constitute a pathway for direct and immediate communication between activated receptor and gene (Figure 1 ).
Just as interferon-y has biological activities that are distinct from and yet overlap those of other immunomodulating factors, such as interferon-c*, interferon-/3, and lipopolysaccharide, so too does interferon-y induce a set of genes and proteins that, although unique, overlaps the sets of genes and proteins induced by these other factors (18) . These relations are reflected in shared components that participate in a combinatorial fashion in forming the protein complexes that transduce signals from ligand-activated receptors to the inducible genes. The Jak kinases and Static* (or closely related STAT proteins) have been shown to participate in signal transduction in response to a range of cytokines and growth factors (15) . Major unanswered questions remain about how the specificity of the response to a given cytokine, such as interferon-y, is determined.
The importance of the activation of specific genes by interferon-y lies, of course, in the encoded proteins that are newly expressed and that alter the physiology of the target cells. Several host defense proteins are induced in response to interferon-y, including products of immediate response (GAS-containing) genes and some proteins whose induction requires the previous synthesis of the protein products of the immediate response genes ( Table  1) . The inducible proteins include surface molecules, such as MHC antigens important for antigen presentation; enzymes, such as the components of the reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and nitric oxide synthase (important in generating reactive oxygen and nitrogen species, respectively, for pathogen killing); transcription factors, such as interferon regulatory factor-1 (an immediate response gene necessary for the induction of the nitric oxide synthase gene); and cytokines, such as tumor necrosis factor-c*.
Although interferon-y is a potent modulator of production of tumor necrosis factor-c*, it is not sufficient to induce tumor necrosis factor-c*; rather, it acts synergistically with other tumor necrosis factor-c* inducers. This raises the general point that interferon-y works not in isolation but in the context of an immune response involving a collection of cell-surface and secreted molecules. One model that places interferon-y in the context of the Interferon-y has a sixhelix monomer structure and exists in solution as an antiparallel homodimer. The interferon-y receptor consists of at least two chains: the a chain, which is both necessary and sufficient for binding, and the /3 chain, which is necessary for signaling. Binding of interferon-y to its receptor leads to receptor dimerization and the phosphorylation of tyrosine residues of interferon-yreceptor a chain and of two tyrosine kinases, Jakl and Jak2. The receptor and the kinases probably exist in a preformed complex before activation by ligand binding, but this has not been shown. Activation of the Jak tyrosine kinases leads to phosphorylation of a latent cytoplasmic factor, Static*, which forms dimers that translocate to the nucleus. Probably together with other proteins (represented by X), Static* binds to sequences that include the GAS motif (consensus sequence TTNCNNNAA) in the promoters of interferon-y-responsive genes, thereby activating transcription. Sequences in addition to the GAS core, indicated by "(and more)," are important for the activation of interferon-y-responsive genes. Arrows pointing to the latent Static* indicate that activation of various cytokine and growth factor receptors, in addition to the interferon-y receptor, leads to phosphorylation of Static* or closely related STAT proteins. P = phosphorylated tyrosine residue.
overall immune response to pathogens is the helper T-cell T H1 /T H2 paradigm (19) . Studies of murine CD4 + T-cell clones in long-term culture have shown that a given clone expresses one of two mutually exclusive phenotypes: the T H1 phenotype (characterized by the production of interferon-y, interleukin-2, and tumor necrosis factor-]3) and the T H2 phenotype (characterized by the production of interleukin-4, interleukin-5, and other related lymphokines). Although first defined and best studied in murine systems, the T H1 /T H2 paradigm, in its general outline, is clearly applicable to humans (20) .
Interferon-y plays a critical role both in inducing the differentiation of CD4 + T cells to the T H1 phenotype and as the major product of T H1 cells, which are important for activating macrophage against intracellular pathogens. As shown in Figure 2 , after activation by a pathogen, the Table 1 , resulting in enhanced killing of pathogens. Interferon-7 also has an inhibitory effect on the development of the T H2 phenotype. In contrast to interferon-7, interleukin-4 and interleukin-10 inhibit T H1 responses and have direct inhibitory effects on the activation of macrophages. The development of effective cell-mediated immunity against intracellular pathogens has been shown in mouse models to depend on the predominance of the T H1 response over the T H2 response and on the production of interferon-7, the signature cytokine of T H1 cells. Given the complexity of the system within which interferon-7 operates and the redundancy in host defense mechanisms, it is reasonable to ask the following question: In which biological responses does interferon-7 play a unique and necessary role? The most unambiguous information about this comes from recent experiments that used mice with targeted disruptions of either the interferon-7 gene (22) or the gene for the binding (a) subunit of the interferon-7 receptor (23). These "knockout mice" are unable to control infections with intracellular pathogens in which macrophages are known to be important, such as infections with the mycobacteria Bacillus Calmette-Guerin (BCG) (24) and Mycobacterium tuberculosis and with Listeria species (23) . When the knockout mice were experimentally infected with BCG, macrophages isolated from these mice showed a decreased ability to produce reactive oxygen species, a complete inability to produce reactive nitrogen species, and decreased expression of MHC class II antigens Figure 2 . Interferon-y (IFN-y) in the cytokine network. A macrophage (MO*) that has been activated by encountering a pathogen secretes interleukin-12, which stimulates T cells and natural killer (NK) cells to secrete interferon-7 and biases the differentiation of CD4 + cells into the T H1 phenotype. Interferon-7 produced by natural killer cells and T H1 cells activates macrophages for pathogen killing through the production of mediators such as superoxide (Oi), nitric oxide (NO-), and cytokines such as tumor necrosis factor-a (TNF-a). Interferon-7 inhibits the production of CD4 + T H2 cells. These cells are characterized by the production of interleukin-4, interleukin-10, and related cytokines. Interleukin-4 inhibits the development of T H1 cells; interleukin-10 inhibits cytokine production by natural killer and T H1 cells; and interleukin-4 and interleukin-10 both antagonize the effects of interferon-7 on macrophage activation. Although this scheme is based on data from studies in mice, the T Hi rr H2 paradigm is applicable to humans. (22) . Infected knockout mice also showed a marked decrease in their production of tumor necrosis factor-a (24) . This last abnormality is of interest because tumor necrosis factor-a is probably one of the important mediators of the action of interferon-7 in such infections and has been shown to play a role both in granuloma formation and in the direct control of mycobacterial infections. In addition, the knockout mice could not deal with vaccinia virus (23), although they had no difficulty in controlling infections with lymphocytic choriomeningitis virus or vesicular stomatitis virus. Therefore, even though interferon-7 is generally regarded as much less important in antiviral defense than interferon-** and -j3, it plays a key role with vaccinia virus. Further studies with these mice will probably show additional unanticipated defects in their ability to deal with specific pathogens.
Because many of the biological findings described above derive from studies in mice, the data may not apply to humans in every detail. For example, the role of nitric oxide as a host defense mechanism in humans remains unsettled because substantial production of nitric oxide by human macrophages has not been shown. Nonetheless, good evidence shows that, as the clinical data below will illustrate, the animal data generally delineate a mechanism of action for interferon-7 that applies to humans.
Chronic Granulomatous Disease
Dr. Gallin: Chronic granulomatous disease is an inherited, life-threatening pediatric immunodeficiency state characterized by recurrent pyogenic infections with catalase-positive microorganisms, excessive granuloma formation, and deficient bactericidal activity by neutrophils and mononuclear phagocytes (25) . The abnormality in chronic granulomatous disease relates to a defect in NADPH oxidase, an enzyme essential for the conversion of molecular oxygen to hydrogen peroxide by phagocytic cells. This enzyme is a complex of at least five proteins; an abnormality in any of four of the proteins accounts for all forms of chronic granulomatous disease (26) . Thus, chronic granulomatous disease is a group of disorders of oxidative metabolism in phagocytic cells, in which different genetic mutations of components in a complex enzyme system result in a common phenotype.
Current therapy for chronic granulomatous disease includes antibiotic prophylaxis with trimethoprim-sulfamethoxazole, prolonged courses of parenteral antibiotics for infections, and aggressive surgical intervention for drainage of abscesses. Some centers, including the National Institutes of Health Warren G. Magnuson Clinical Center, use leukocyte transfusions for life-threatening infections. In 1991, partly because of a multicenter, doubleblind study done in the United States and Europe in which interferon-7 reduced the frequency of infection by more than 70% in patients with chronic granulomatous disease (27) , the Food and Drug Administration approved the prophylactic use of subcutaneous interferon-7 in patients with chronic granulomatous disease. As a consequence, most physicians have begun using interferon-7 as a prophylactic agent in the management of chronic granulomatous disease.
Curnutte and colleagues (28) reported that 30 patients with chronic granulomatous disease, who were evaluated for 12 months while receiving interferon-7 after completion of the above study (27) , had an incidence of 0.13 infections per patient-year. This was substantially less than the rate of 1.16 infections per patient-year seen in the placebo group in the double-blind study. The major reported adverse effects (fever, mild liver enzyme abnormalities, and mild neutropenia) were transient and resolved with dose reduction. Curnutte and colleagues concluded that interferon-7 therapy was effective and did not have unexpected toxicities. We followed 34 patients at the National Institutes of Health Warren G. Magnuson Clinical Center who received interferon-7 for 3 years after the above-described double-blind study (27) was completed. Twenty-six of the patients with chronic granulomatous disease were children. No unexpected side effects were noted; normal growth and development occurred in the 26 children receiving the subcutaneous interferon-7 injection (50 jbtg/m 2 body surface area) three times per week. The major toxicities seen were headache, fever, and myalgias. In most patients, these side effects were relieved by pretreatment with acetaminophen. In a few patients, it was necessary to halve the dose of interferon-7 to achieve tolerance.
During the 3 years since the above-mentioned study (27) , it has been our impression that patients with chronic granulomatous disease who are receiving interferon-7 have more pronounced clinical and febrile reactions to infections. Thus, interferon-7 helps the family and the physician recognize when a clinical event is serious and warrants an extensive work-up.
It is difficult to assess the benefit of interferon-7 in a phase IV follow-up study, because there can be no randomization of patients in such a study. This is particularly relevant because some participants in the original study (27) believed that they had less severe disease and declined to receive the agent during the phase IV follow-up. Furthermore, compliance was a problem in the phase IV study, especially among persons in adolescent populations. Nonetheless, 34 patients had well-documented periods of receiving and not receiving interferon-7 during the phase IV study. The incidence of infection when the patients were receiving or not receiving interferon-7 was assessed, allowing for a 1-month washout period when the patients were not receiving interferon-7. In this group of patients, there were 1189 patient-months receiving and 648 patient-months not receiving interferon-7. The incidence of bacterial infections was 0.528 per patient-year receiving interferon-7 and 0.372 per patient-year not receiving the drug; the difference was not significant (P = 0.24). Similarly, the incidence of fungal infection did not differ significantly between those receiving and those not receiving interferon-7: The incidence per patient-year was 0.144 receiving interferon-7 and 0.168 not receiving interferon-7 (P > 0.05). Thus, the incidence of infections in patients with chronic granulomatous disease who received interferon-7 for 3 years after the completion of the double-blind trial was lower than that in the group receiving placebo in the double-blind trial (27) , as noted by Curnutte and colleagues (28) . However, there was no significant difference in infection rates in patients who stopped receiving interferon-7 after prolonged use. This finding suggests that patients receiving interferon-7 regularly for 1 to 3 years have a sustained benefit after therapy with the agent is discontinued, as originally suggested by Sechler and coworkers (29) . The possibility that the effects of interferon-y are sustained warrants further investigation to determine the appropriate frequency and duration of interferon-y administration for prophylactic use in diseases such as chronic granulomatous disease.
Mycobacteria
Dr. Steven M. Holland (Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases): To date, two types of mycobacterial infections have been treated with interferon-y: leprosy and infection with M. avium complex. Leprosy is caused by M. leprae, the Hansen disease bacillus, and afflicts about 12 million persons worldwide. It is probably transmitted from human to human, although not efficiently. Initial infection with M. leprae results in an indeterminate lesion that may progress into one of several subtypes of leprosy, the two polar forms of which are tuberculoid and lepromatous. Tuberculoid disease is characterized by circumscribed, contained infection; good immune response to M. leprae antigens; good granuloma formation; and few organisms seen in biopsy specimens. In contrast, lepromatous disease is characterized by diffuse, destructive tissue infiltration; no immune response to M. leprae antigens; no granuloma formation; and abundant organisms seen in biopsy specimens. During treatment for lepromatous leprosy, many patients have exacerbations of immune responses, including erythema nodosum leprosum, in which painful erythematous, subcutaneous plaques erupt and may ulcerate.
Some of the differences between tuberculoid and lepromatous leprosy appear to be due to differences in cytokine production. Yamamura and colleagues (30) measured cytokine messenger RNA (mRNA) levels in skin biopsy samples from tuberculoid and lepromatous lesions and found that interferon-y and interleukin-2 messenger RNAs were more abundant in tuberculoid lesions, whereas interleukin-4, interleukin-5, and interleukin-10 mRNAs were more abundant in lepromatous lesions. These findings conform to the T H1 and T H2 phenotypes predicted from mouse models (Figure 2 ). The relative abundance of interferon-y in contained, circumscribed (tuberculoid) disease and its relative paucity in diffuse, disseminated (lepromatous) disease help provide a pathophysiologic rationale for the use of interferon-y in the treatment of lepromatous leprosy.
Most studies of the treatment of leprosy with interferon-y have used short-term intralesional administration (31) . In general, the studies have used 3 to 6 doses of 10 to 20 jLtg each for 3 to 10 days. These studies have followed bacillary counts, lesional histology, cellular activation markers, and superoxide production. One study gave somewhat higher doses for 6 to 10 months after an induction period (32) . The results have been encouraging. In studies in which interferon-y was given in combination with antimycobacterial agents, bacillary counts in lesions in patients receiving combination therapy clearly decreased more than they did in patients receiving drug therapy alone. Lesional granuloma formation was enhanced, as was monocyte superoxide generation. Intralesional administration also induced keratinocyte expression of MHC class II antigens, a marker of immune activation. In the one study in which long-term intralesional interferon-y therapy was given, 60% of patients receiving interferon-y and 15% of controls developed erythema nodosum leprosum (32) . Strategies for the effective suppression of erythema nodosum leprosum in these types of patients are now being studied (32) .
Despite widespread exposure, serious M. avium complex infections are rare in normal hosts. Localized pulmonary disease may develop in patients with underlying structural lung disease, such as smokers. Disseminated disease may occur in immunocompromised patients, such as those with cancer or those receiving immunosuppressive agents (33) . As many as 40% of patients with the acquired immunodeficiency syndrome (AIDS) may develop disseminated M. avium complex infection (34) . To better understand host resistance to mycobacterial infections, we identified and treated patients with disseminated M. avium complex infections who did not have cancer, were not infected with the human immunodeficiency virus (HIV), and were not receiving immunosuppressive agents (35) . The patients had extensive disease involving multiple organ systems. All had received aggressive antimycobacterial chemotherapy but had remained ill. Because these patients had no known immune defects, either endogenous or acquired, we looked at their ability to generate certain cytokines, such as interferon-y. When peripheral blood mononuclear cells from these patients were stimulated with the T-cell mitogen phytohemagglutinin, they produced significantly less interferon-y than did peripheral blood mononuclear cells from normal persons (35) . This finding, together with previous work on leprosy and intracellular parasites, served as a rationale for using interferon-y in addition to antimycobacterial agents in the treatment of these patients. In contrast to the treatment of leprosy, we gave interferon-y subcutaneously at the same dosage used to treat chronic granulomatous disease (50 /xg/m 2 body surface area three times/wk). Treatment continued for 4 to 19 months or more, and the results have been encouraging. The seven patients treated had rapid responses in clearing of infected foci and blood cultures, abatement of fever, and improvement in subjective well-being. The drug was well tolerated over long periods. No exacerbations of underlying disease and no immune exacerbations, such as erythema nodosum leprosum, have occurred. We have seen no rebound of symptoms in the patients who have stopped receiving interferon-y.
Interferon-y has been used in a few patients with AIDS-associated M. avium complex infection. Squires and colleagues (36, 37) have published results on six patients who were given interferon-y either intravenously or subcutaneously, about 100 /xg/m 2 body surface area three times weekly for 4 to 6 weeks. These studies showed that interferon-y was well tolerated and led to a substantial reduction in levels of M. avium complex bacteremia in all patients when used with antimycobacterial agents, but not when used without antimycobacterial agents.
There are probably several mechanisms by which interferon-y helps to clear mycobacterial infections. Phagocyte oxidative metabolism is clearly elevated by the administration of interferon-y (31). Nonoxidative microbicidal 46 47 pathways are also augmented; these include the release of antimicrobial granule proteins, the degradation of tryptophan, prostaglandin synthesis, T-cell development, cytokine production, and antigen processing and presentation (1) . In vitro, interferon-y increases the intracellular concentration of certain antibiotics, particularly macrolides (38) . This may help to explain the importance of the simultaneous administration of interferon-7 and antimycobacterial agents.
Protozoal Infections and Hyper-IgE States
Dr. Thomas B. Nutman (Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases): The practice of using interferon-7 in parasitic protozoal infections and in states associated with extreme elevations of IgE is based on two distinct, important actions of interferon-7. For protozoan parasites, for which the infection is intracellular (primarily within macrophages), interferon-7 provides one of the major signals for activation of the macrophage, a process required for killing the parasite. Interferon-7 also appears to enhance the accumulation of chemotherapeutic agents within the macrophage, so that higher levels of a specific antiprotozoal agent are delivered to the site where the parasite lives (39) . In hyper-IgE states (such as atopic dermatitis or the hyper-IgE recurrent infection [Job] syndrome), interferon-7 is used because it can down-regulate the production of IgE either by acting directly on the B lymphocyte itself or by modulating the expression of interleukin-4, the major cytokine involved in antibody class switch recombination to IgE.
Protozoal Infections
Toxoplasmosis and leishmaniasis are caused by obligate intracellular protozoa. In both infections, the production of interferon-7 has been shown, at least experimentally, to be absolutely critical for clearance of the parasite (39) . Thus, it is in these two protozoal infections that interferon-7 has been either used (40) (41) (42) (43) (44) (45) (46) (47) (48) or considered for use in human infection.
Leishmanial Infection
The leishmaniases are caused by several genetically distinct intracellular parasites of Leishmania species, which are found worldwide. Both the clinical and the immunologic manifestations of leishmaniasis cover a wide spectrum, from localized cutaneous disease, with its associated strong delayed-type hypersensitivity reactions to leishmanial antigen, to the visceral form of the disease (kala-azar), which is associated with an inability to respond immunologically to leishmanial antigen.
The localized cutaneous form and the mucocutaneous form of leishmaniasis (in which both the skin and mucosal surfaces are involved) are characterized by the development of single or multiple ulcerating lesions that are initially found on exposed areas of the skin. Cutaneous leishmaniasis usually heals spontaneously. In Central and South America, where mucocutaneous disease occurs in as many as 2% to 5% of infected patients, spontaneous healing is somewhat less common. Both forms of leishmanial infection are associated with strong parasite-specific immune responses, including the production of interferon-7 (49), but in some situations the infection is neither self-limited nor sensitive to available chemotherapy. In single cases (Table 2 ) of patients with cutaneous or mucocutaneous leishmaniasis who were refractory to standard chemotherapy (pentavalent antimony), adding interferon-7 to the pentavalent antimony caused remission (44) . Adding interferon-7 to the antimony regimen has been shown to allow a shorter duration (10 rather than 20 days) of antileishmanial drug administration (47) . In one patient with refractory cutaneous leishmaniasis, adding interferon-7 to a regimen that included antimony induced healing (46) .
Visceral leishmaniasis (kala-azar) is characterized by fever, massive hepatosplenomegaly, profound anemia, leukopenia, and thrombocytopenia, and it is often fatal without therapy. Visceral leishmaniasis and the diffuse cutaneous form of leishmaniasis, in which skin lesions are widely disseminated (plaques, papules, and nodules), are forms of the infection that are associated with profound immunologic defects. Patients with diffuse cutaneous leishmaniasis do not mount a delayed-type hypersensitivity response to intradermally administered leishmanial antigen or to recall antigens, such as Candida albicans or purified protein derivative. Lymphocytes from these patients cannot produce either interleukin-2 or interferon-7 in response to leishmanial antigen (50) . Finally, this lack of interferon-7, the cytokine responsible not only for inducing macrophages to kill leishmanial parasites but for concentrating the chemotherapeutic agents (such as pentavalent antimony [39] within macrophages), led to its use as an adjuvant to standard chemotherapy for these forms of leishmaniasis (Table 2 ).
Toxoplasmosis
Evidence indicates that the administration of cytokines, particularly interferon-7, could be useful as adjuvant ther- apy in the treatment of toxoplasmosis. Both interferon-y and interleukin-2 have been shown to be important in controlling toxoplasmosis (42) . Interferon-y can inhibit the replication of Toxoplasma gondii in vitro. Indeed, in animal models of acute toxoplasmosis, administration of either interferon-y (51) or interleukin-12, a cytokine that induces interferon-y (52), has been shown to increase survival. Conversely, administration of neutralizing antibodies to interferon-y has been shown to decrease survival (50) . Finally, in several cases of persons with HIV infection who were receiving interferon-y or interleukin-2, monocytes obtained during cytokine administration had a greater ability to inhibit the growth of T. gondii than did those obtained earlier or later (53, 54) . Studies are under way to examine the utility of interferon-y as an adjunct to chemotherapy.
Hyper-IgE States.
The use of interferon-y in states associated with extreme elevations of serum IgE levels derives from the ability of interferon-y to regulate the production of IgE by B lymphocytes. Interferon-y acts directly on appropriately differentiated B cells to induce them to produce antibody isotypes other than IgG4 or IgE (namely, IgGl, IgG2, and IgG3). In addition, because interferon-y is a potent inhibitor of T-cell interleukin-4 production, less interleukin-4 is available to induce B-cell switching to IgE. Thus, theoretically, interferon-y acts at several levels (B cells and T cells) to downregulate IgE production.
The two conditions associated with extreme elevations in serum IgE levels in which interferon-y has been used therapeutically are the hyper-IgE recurrent infection syndrome (the Job syndrome) and atopic dermatitis. The hyper-IgE recurrent infection syndrome is characterized clinically by eczematoid rashes, a particular facial appearance, recurrent deep and subcutaneous infections, and kyphoscoliosis. Atopic dermatitis is an inflammatory skin disease characterized by dermatitis and severe pruritus. Both the hyper-IgE syndrome and atopic dermatitis are associated with immunologic defects and produce serum IgE levels that are among the highest recorded. In atopic dermatitis, the elevated IgE levels have reflected both overproduction of interleukin-4 (55) and a defect in the production of interferon-y (56, 57) . Because good therapeutic methods do not exist for either of these clinical conditions, and because interferon-y was believed to be capable of reversing several of the associated immunologic abnormalities, interferon-y has been administered for these two conditions (Table 3 ). In the hyper-IgE syndrome, interferon-y reduced IgE production both in vitro and in vivo in most patients, although no clear clinical improvement was seen. In contrast, in most patients with atopic dermatitis, many of whom had severe manifestations refractory to standard therapy, interferon-y was clinically beneficial. Interestingly, the clinical benefit was not related to IgE reduction in this group of patients.
Thus, the systemic administration of interferon-y is clearly shown to have clinical benefit in persons with atopic dermatitis, but its utility in the hyper-IgE recurrent infection syndrome remains to be established. In neither of these conditions and in none of the diseases mentioned above have controlled trials been done to optimize the dosage, the intervals between doses, or the duration of therapy needed to sustain continued benefit from the administration of interferon-y.
Conclusion
Dr. Gallin: Interferon-y is currently licensed for only one indication: the reduction of life-threatening infections in chronic granulomatous disease. However, increasing evidence indicates that interferon-y is important in the therapy for certain intracellular infections, such as leishmaniasis, toxoplasmosis, and infections by atypical mycobacteria and M. leprae. Interferon-y exerts its effects through pleiotropic modulation of the host defenses. Understanding the molecular mechanisms of interferon-y action may lead to the ability to enhance or inhibit specific subsets of the effects of interferon-y. A 3-year follow-up of patients with chronic granulomatous disease who have received interferon-y suggests that the beneficial effects of this drug may be sustained. Future studies of interferon-y need to focus on several points. First, the mechanisms of the drug's therapeutic and prophylactic effects must be understood. Addressing these mechanisms in human models of disease will probably not be possible. The development of mouse models of chronic granulomatous disease will allow dissection of the critical pathways involved in prophylaxis for infections. Second, other modes of delivery may be more effective than the subcutaneous route; we currently use aerosolized interferon-y for pulmonary infections. The roles for interferon-y therapy in multi-drug-resistant tuberculosis and fungal infections are also being explored. The role of interferon-y in the prevention and treatment of opportunistic infections in patients with AIDS has not been prospectively explored, and more work is clearly needed in this area. Finally, optimal dose and duration of therapy are unknown and require prospective study.
